Methotrexate: A new treatment in opsoclonus-myoclonus syndrome

Christian Denne; Michael Kleines; Simone Scheithauer; Gerhard Heimann; Martin Häusler

doi:10.1055/s-0035-1557328

Journal of Pediatric Neurology, Inhaltsverzeichnis

Journal of Pediatric Neurology 2006; 04(03): 183-185
DOI: 10.1055/s-0035-1557328

Case Report

Georg Thieme Verlag KG Stuttgart – New York

Methotrexate: A new treatment in opsoclonus-myoclonus syndrome

Autor*innen

Christian Denne

^aDepartment of Pediatrics, RWTH, University Hospital Aachen, Aachen, Germany
Michael Kleines

^bDepartment of Virology, RWTH, University Hospital Aachen, Aachen, Germany
Simone Scheithauer

^bDepartment of Virology, RWTH, University Hospital Aachen, Aachen, Germany
Gerhard Heimann

^aDepartment of Pediatrics, RWTH, University Hospital Aachen, Aachen, Germany
Martin Häusler

^aDepartment of Pediatrics, RWTH, University Hospital Aachen, Aachen, Germany

Verantwortlicher Herausgeber dieser Rubrik:

Abstract

als PDF herunterladen

Abstract

We report a girl with opsoclonus-myoclonus syndrome related to cerebral rubella infection that relapsed during adrenocorticotropin monotherapy but stabilized with methotrexate add-on treatment. Methotrexate may be a new therapeutic option in opsoclonus-myoclonus syndrome, reducing the need for long-term high-dose adrenocorticotropin treatment and the risk of steroid-related side effects.

Keywords

Opsoclonus - myoclonus - methotrexate - ACTH - rubella

PDF (32 kb)